PRISM BioLab Co.,LTD (206A.T)
JPY 244.0
(-4.69%)
JPY 244.0
(-4.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.13 Billion JPY | 32.82% |
| 2022 | -1.68 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -3.07 Billion JPY | -3.74% |
| 2024 Q2 | -2.96 Billion JPY | 0.0% |
| 2023 FY | -1.13 Billion JPY | 32.82% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 252.666% |
| GNI Group Ltd. | -17.93 Billion JPY | 93.677% |
| Linical Co., Ltd. | -4.46 Billion JPY | 74.594% |
| Trans Genic Inc. | -221.16 Million JPY | -412.704% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 74.194% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 76.327% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 179.101% |
| AnGes, Inc. | -3.79 Billion JPY | 70.142% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -169.469% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 104.553% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -127.629% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -143.154% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 58.097% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 39.946% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -15.456% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 66.619% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -9.607% |
| Kidswell Bio Corporation | 343.58 Million JPY | 430.029% |
| PeptiDream Inc. | 3.29 Billion JPY | 134.445% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -16.59% |
| Ribomic Inc. | -2.09 Billion JPY | 45.996% |
| SanBio Company Limited | -3.78 Billion JPY | 70.078% |
| Healios K.K. | -2.19 Billion JPY | 48.222% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -20.012% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 56.788% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 19.979% |
| StemRIM | -8.41 Billion JPY | 86.517% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 75.788% |
| FunPep Company Limited | -1.79 Billion JPY | 36.771% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 46.925% |
| Stella Pharma Corporation | -1.11 Billion JPY | -1.299% |
| TMS Co., Ltd. | -3.44 Billion JPY | 67.1% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 79.59% |
| Cuorips Inc. | -5.56 Billion JPY | 79.609% |
| K Pharma,Inc. | -3.26 Billion JPY | 65.285% |
| Takara Bio Inc. | -32.2 Billion JPY | 96.479% |
| ReproCELL Incorporated | -2.93 Billion JPY | 61.418% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -71.56% |
| StemCell Institute Inc. | -2.83 Billion JPY | 60.027% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 45.123% |
| CellSeed Inc. | -2.01 Billion JPY | 43.642% |